tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2012 Jan;11(1):17-25.
Fluzone(?) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults.
Ansaldi F, de Florentiis D, Durando P, Icardi G.
Source
Department of Health Sciences, University of Genoa, Via A. Pastore 1, 16132 Genoa, Italy.
Abstract
On May 9 2011, the US FDA approved Sanofi Pasteur's Fluzone(?) Intradermal influenza vaccine, the first influenza vaccine licensed in the USA that uses a new microinjection system for intradermal delivery of vaccines (Soluvia?, Becton Dickinson). Its antigen content is lower (9 ?g hemagglutinin per strain) than the conventional intramuscular vaccine (15 ?g) and it is indicated for active immunization of adults aged between 18 and 64 years. Data from the clinical trial assessing immunogenicity and safety of Fluzone Intradermal in adults were consistent with substantial experience accumulated with Intanza(?) 9 ?g, the intradermal vaccine licensed on February 26 2009 and launched during the 2010/2011 season in Europe. Fluzone Intradermal is safe and its immunogenicity comparable with that of conventional intramuscular vaccines. Obtaining optimal acceptability of intradermal vaccines may represent an additional asset to help increase the coverage of influenza vaccination in young adults.
PMID:
22149703
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22149703
Fluzone(?) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults.
Ansaldi F, de Florentiis D, Durando P, Icardi G.
Source
Department of Health Sciences, University of Genoa, Via A. Pastore 1, 16132 Genoa, Italy.
Abstract
On May 9 2011, the US FDA approved Sanofi Pasteur's Fluzone(?) Intradermal influenza vaccine, the first influenza vaccine licensed in the USA that uses a new microinjection system for intradermal delivery of vaccines (Soluvia?, Becton Dickinson). Its antigen content is lower (9 ?g hemagglutinin per strain) than the conventional intramuscular vaccine (15 ?g) and it is indicated for active immunization of adults aged between 18 and 64 years. Data from the clinical trial assessing immunogenicity and safety of Fluzone Intradermal in adults were consistent with substantial experience accumulated with Intanza(?) 9 ?g, the intradermal vaccine licensed on February 26 2009 and launched during the 2010/2011 season in Europe. Fluzone Intradermal is safe and its immunogenicity comparable with that of conventional intramuscular vaccines. Obtaining optimal acceptability of intradermal vaccines may represent an additional asset to help increase the coverage of influenza vaccination in young adults.
PMID:
22149703
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22149703